Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Athenex Inc (ATNX)

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 663,627
  • Shares Outstanding, K 81,627
  • Annual Sales, $ 101,230 K
  • Annual Income, $ -123,750 K
  • 60-Month Beta 0.21
  • Price/Sales 6.07
  • Price/Cash Flow N/A
  • Price/Book 3.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.21
  • Number of Estimates 2
  • High Estimate 0.08
  • Low Estimate -0.50
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +60.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.63 +37.48%
on 03/18/20
13.32 -41.91%
on 03/04/20
-4.48 (-36.66%)
since 02/28/20
3-Month
5.63 +37.48%
on 03/18/20
16.04 -51.75%
on 01/09/20
-7.54 (-49.35%)
since 12/27/19
52-Week
5.63 +37.48%
on 03/18/20
21.11 -63.33%
on 07/09/19
-4.51 (-36.82%)
since 03/29/19

Most Recent Stories

More News
Athenex Provides a Corporate Update

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 7.74 (-4.80%)
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced...

ATNX : 7.74 (-4.80%)
Athenex (ATNX) Moves to Buy: Rationale Behind the Upgrade

Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ATNX : 7.74 (-4.80%)
Athenex's Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, provided...

ATNX : 7.74 (-4.80%)
Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of 44.00% and 185.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ATNX : 7.74 (-4.80%)
Athenex: 4Q Earnings Snapshot

BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Thursday reported a loss of $21.7 million in its fourth quarter.

ATNX : 7.74 (-4.80%)
Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update

-- Oral Paclitaxel NDA submission is on track; Final FDA meeting scheduled for early April

ATNX : 7.74 (-4.80%)
Athenex, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 27, 2020 / Athenex, Inc. (NASDAQ:ATNX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 27, 2020 at 8:00...

ATNX : 7.74 (-4.80%)
Athenex Announces Participation at the Cowen 40th Annual Health Care Conference

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that management...

ATNX : 7.74 (-4.80%)
Big Advances in Breast Cancer Screening Creating Sizable Opportunities

While we should all be diligent in cancer detection and treatment in every month of the year, February is well known as National Cancer Prevention Month. It's an annual campaign to increase awareness of...

IZO.CN : 0.140 (-6.67%)
IZOZF : 0.1101 (+35.26%)
HOLX : 35.10 (+0.29%)
ATNX : 7.74 (-4.80%)
SGEN : 115.38 (+0.08%)
CLVS : 6.36 (-1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ATNX with:

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

2nd Resistance Point 8.57
1st Resistance Point 8.16
Last Price 7.74
1st Support Level 7.37
2nd Support Level 6.99

See More

52-Week High 21.11
Fibonacci 61.8% 15.20
Fibonacci 50% 13.37
Fibonacci 38.2% 11.54
Last Price 7.74
52-Week Low 5.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar